SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
tuoqi
Lv2
150 积分
2022-12-14 加入
最近求助
最近应助
互助留言
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor
4天前
已完结
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
15天前
已完结
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
1个月前
已完结
TFE3-splicing factor fusions represent functional drivers and druggable targets in translocation renal cell carcinoma
1个月前
已完结
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
2个月前
已关闭
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer
2个月前
已完结
Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma
2个月前
已完结
Neratinib: First Global Approval
2个月前
已完结
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
2个月前
已完结
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
2个月前
已完结
没有进行任何应助
找到了【积分已退回】
2个月前
重新求助了【积分已退回】
4个月前
点赞
4个月前
帮大忙了
8个月前
帮大忙了
8个月前
速度真快,帮大忙了
8个月前
速度真快
9个月前
感谢,点赞,速度真快
11个月前
感谢,点赞,速度真快,帮大忙了
11个月前
速度真快,点赞,感谢
11个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论